Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials [version 1; peer review: 1 approved with reservations]

• Main Authors: Gatot Soegiarto, -, Jonny Fajar, -, Laksmi Wulandari, -, Muhammad Anshory, -, Muhammad Ilmawan, -, Anisa Asmiragani, -, Himma Illiyana, -, Azaria Adam, -, Sutini Lamadi, -, Umi Sa'adah, -, Tubagus Yuantoko, -, Esi Nanda, -, Farida Rachmawati, -, Nabila Rahmadani, -, Randy Talilah, -, Madyline Katipana, -, Sharon Susanto, -, Maria Hindom, -, Ufi Anjasari, -, Nur Hidayah, -, Nanda Fadila, -, Vanela Lekatompessy, -, Uzi Phoenna, -, Fredo Tamara, -, Dessy Kartini, -, Aditya Mahendra, -, Andi Permana, -, Erwin Pasaribu, -, Kuldeep Dhama, -, Harapan, -
• Format: Article PeerReviewed
• Language: English; English; English
• Published: Taylor & Francis 2022
• Subjects: R Medicine (General); RC Internal medicine
• Online Access: https://repository.unair.ac.id/119283/1/2.pdf; https://repository.unair.ac.id/119283/2/Artikel%201.pdf; https://repository.unair.ac.id/119283/3/Turnitin%20Artikel%201.pdf; https://repository.unair.ac.id/119283/; https://f1000research.com/articles/11-299/v1; https://doi.org/10.12688/f1000research.110281.1
• Institution: Universitas Airlangga

BACKGROUND: The COVID-19 vaccination program, which uses various types of vaccines, has been applied since the beginning of 2021. However, the efficacy in the context of seroconversion rate remains unclear. OBJECTIVE: To assess the seroconversion rates among different COVID-19 vaccines using a network meta-analysis approach. METHODS: A network meta-analysis of randomized controlled trials (RCTs) was conducted during the study period. Data of interest, such as seroconversion rate and the type of COVID-19 vaccine, were extracted from each study. The analysis was performed using single-arm analysis by calculating the cumulative seroconversion rate. A network meta-analysis was conducted using the Bayesian method. RESULTS: A total of 31 RCTs were included in our analysis. Our pooled calculation revealed that the seroconversion rates of inactivated messenger ribonucleic acid (mRNA), protein subunit, and vector COVID-19 vaccines during the follow-up periods were 93.2%, 93.9%, 65.3%, and 54.7%, respectively, at ≤ 15 days; 96.0%, 94.8%, 91.2%, and 89.7%, respectively, between days 16–30; and 98.5%, 98.6%, 98.5%, and 96.2%, respectively, between days 31–60.The indirect comparison revealed that in the follow-up periods of ≤ 15 and 16–30 days, the inactivated and mRNA COVID-19 vaccines had superior seroconversion rates compared with those of the protein subunit and vector vaccines. In the follow-up period of 31–60 days, the highest seroconversion rates were found in the inactivated, mRNA, and protein subunit COVID-19 vaccines. CONCLUSION: This study provides valuable information regarding the comparison of seroconversion rates of COVID-19 vaccines.